Users of Alpha-blockers (OR, 0.88; 95% CI, 0.79–0.98), ACE inhibitors (OR, 0.92; 95% CI, 0.84–0.90), and ARBs (OR, 0.92; 95% CI, 0.82–0.99) were at a lower risk of developing NOD than nonusers. Here, ACE is linked to dentatorubral-pallidoluysian atrophy.